| Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial SB Kang, JW Park, SY Jeong, BH Nam, HS Choi, DW Kim, SB Lim, ... The lancet oncology 11 (7), 637-645, 2010 | 1224 | 2010 |
| Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority … SY Jeong, JW Park, BH Nam, S Kim, SB Kang, SB Lim, HS Choi, DW Kim, ... The Lancet Oncology 15 (7), 767-774, 2014 | 1009 | 2014 |
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 988 | 2005 |
| Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy … YS Hong, BH Nam, K Kim, JE Kim, SJ Park, YS Park, JO Park, SY Kim, ... The lancet oncology 15 (11), 1245-1253, 2014 | 428 | 2014 |
| Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance H Seol, HJ Lee, Y Choi, HE Lee, YJ Kim, JH Kim, E Kang, SW Kim, ... Modern pathology 25 (7), 938-948, 2012 | 357 | 2012 |
| Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer AN Seo, HJ Lee, EJ Kim, HJ Kim, MH Jang, HE Lee, YJ Kim, JH Kim, ... British journal of cancer 109 (10), 2705-2713, 2013 | 352 | 2013 |
| Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt … SW Han, TY Kim, YK Jeon, PG Hwang, SA Im, KH Lee, JH Kim, DW Kim, ... Clinical Cancer Research 12 (8), 2538-2544, 2006 | 330 | 2006 |
| High EGFR gene copy number predicts poor outcome in triple-negative breast cancer HS Park, MH Jang, EJ Kim, HJ Kim, HJ Lee, YJ Kim, JH Kim, E Kang, ... Modern pathology 27 (9), 1212-1222, 2014 | 304 | 2014 |
| Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ... Breast Cancer Research 13, 1-7, 2011 | 297 | 2011 |
| Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer JW Kim, KH Nam, SH Ahn, DJ Park, HH Kim, SH Kim, H Chang, JO Lee, ... Gastric cancer 19, 42-52, 2016 | 283 | 2016 |
| Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the … B Keam, SA Im, HJ Kim, DY Oh, JH Kim, SH Lee, EK Chie, W Han, ... BMC cancer 7, 1-11, 2007 | 249 | 2007 |
| An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer HE Lee, JH Kim, YJ Kim, SY Choi, SW Kim, E Kang, IY Chung, IA Kim, ... British journal of cancer 104 (11), 1730-1738, 2011 | 239 | 2011 |
| Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer DY Kim, JH Kim, SH Lee, TY Kim, DS Heo, YJ Bang, NK Kim Annals of oncology 14 (3), 383-387, 2003 | 234 | 2003 |
| Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy HW Jung, JW Kim, JY Kim, SW Kim, HK Yang, JW Lee, KW Lee, DW Kim, ... Supportive care in cancer 23, 687-694, 2015 | 229 | 2015 |
| The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery YH Yun, YA Kim, YH Min, S Park, YJ Won, DY Kim, IJ Choi, YW Kim, ... Annals of oncology 23 (10), 2731-2737, 2012 | 205 | 2012 |
| The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer J Rhee, SW Han, DY Oh, JH Kim, SA Im, W Han, I Ae Park, DY Noh, ... BMC cancer 8, 1-8, 2008 | 198 | 2008 |
| Promoter CpG island hypermethylation during breast cancer progression SY Park, HJ Kwon, HE Lee, HS Ryu, SW Kim, JH Kim, IA Kim, N Jung, ... Virchows Archiv 458, 73-84, 2011 | 197 | 2011 |
| JARID1B is a luminal lineage-driving oncogene in breast cancer S Yamamoto, Z Wu, HG Russnes, S Takagi, G Peluffo, C Vaske, X Zhao, ... Cancer cell 25 (6), 762-777, 2014 | 188 | 2014 |
| Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era JH Park, YJ Kim, JO Lee, KW Lee, JH Kim, SM Bang, JH Chung, JS Kim, ... Lung Cancer 76 (3), 387-392, 2012 | 187 | 2012 |
| Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer MJ Kim, HS Lee, JH Kim, YJ Kim, JH Kwon, JO Lee, SM Bang, KU Park, ... BMC cancer 12, 1-10, 2012 | 171 | 2012 |
